文献速递呼吸衰竭与机械通气中毒与环境急症

2019年加利福尼亚州与使用电子烟或雾化产品相关的严重肺损伤

Severe Lung Injury Associated With Use of e-Cigarette, or Vaping, Products-California, 2019.
PubMed 文献 · JAMA Intern Med · 2020-01-01
一句话结论加州160例EVALI住院患者中46%入住ICU、29%需机械通气、4例院内死亡;多数使用非正规来源的THC产品,检测的THC产品中84%含维生素E或维生素E醋酸酯。

本报告描述2019年8月7日至11月8日加州向州公共卫生部报告的160例住院EVALI患者的临床特征与雾化产品暴露。患者中62%为男性,中位年龄27岁(范围14-70岁);46%入住ICU,29%需机械通气,发生4例院内死亡。访谈的86例中83%报告使用含THC产品,75%的THC产品来自朋友、熟人或不法零售商等非正规来源。检测的87件产品中56%含THC,含THC产品中84%检出维生素E或维生素E醋酸酯,尼古丁产品中未检出。加州公共卫生部建议在调查期间避免使用任何雾化或电子烟产品,尤其是非正规来源的含THC产品。

要点

  • 160例住院EVALI患者中71例(46%)入住ICU,46例(29%)需机械通气,发生4例院内死亡。
  • 86例受访患者中71例(83%)使用含THC产品,其中65/87件(75%)THC产品来自朋友、熟人或无证零售商等非正规来源。
  • 87件检测产品中49件(56%)含THC;含THC产品中41件(84%)检出维生素E或维生素E醋酸酯,尼古丁产品中未检出。
  • 加州公共卫生部建议:调查期间避免使用任何雾化或电子烟产品,尤其是非正规来源的含THC产品。
  • 作者指出,尽管加州有合法娱乐用大麻市场,患者雾化行为与临床表现与其他州报告相似。

适用人群与场景

  • 2019年8月7日至11月8日向加州公共卫生部报告的160例住院EVALI患者,由治疗临床医生报告至当地卫生部门。
  • 患者中99例(62%)为男性,中位年龄27岁(范围14-70岁)。

研究设计与关键结果

  • 病例系列:160例住院EVALI患者,来自加州当地卫生部门报告;采用标准化患者访谈评估雾化产品使用、使用频率及获取方式,并对部分患者提供的产品检测成分。
  • 156例有数据患者中71例(46%)入住ICU,46例(29%)需机械通气,发生4例院内死亡。
  • 86例受访患者中71例(83%)报告使用含THC产品,36例(43%)使用含CBD产品,39例(47%)使用含尼古丁产品。
  • 87件THC产品中65件(75%)报告来自朋友、熟人或无证零售商等非正规来源。
  • 24例患者提供的87件检测产品中49件(56%)含THC;含THC产品中41件(84%)检出维生素E或维生素E醋酸酯,尼古丁产品中未检出。

证据类型、等级与局限

  • 证据类型:病例系列(加州公共卫生部报告的住院EVALI患者流行病学与实验室数据)。
  • 作者指出,多数检测的THC产品含维生素E或维生素E醋酸酯,但其他潜在损伤原因仍可能存在。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 加州公共卫生部建议:在调查进行期间,个人应避免使用任何雾化或电子烟产品,尤其是非正规来源的含THC产品。

指南或共识出处

  • 加州公共卫生部(California Department of Public Health)建议,引自本报告结论与相关性部分。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Since August 2019, more than 2700 patients have been hospitalized with e-cigarette, or vaping, product use-associated lung injury (EVALI) across the United States. This report describes the outbreak in California, a state with one of the highest case counts and with a legal adult-use (recreational) cannabis market.

OBJECTIVE: To present clinical characteristics and vaping product exposures of patients with EVALI in California.

DESIGN, SETTING, AND PARTICIPANTS: Case series describing epidemiologic and laboratory data from 160 hospitalized patients with EVALI reported to the California Department of Public Health by local health departments, who received reports from treating clinicians, from August 7 through November 8, 2019.

EXPOSURES: Standardized patient interviews were conducted to assess vaping products used, frequency of use, and method of product acquisition. Vaping products provided by a subset of patients were tested for active ingredients and other substances.

MAIN OUTCOMES AND MEASURES: Demographic and clinical characteristics, level of care, and outcomes of hospitalization were obtained from medical record review.

RESULTS: Among 160 patients with EVALI, 99 (62%) were male, and the median age was 27 years (range, 14-70 years). Of 156 patients with data available, 71 (46%) were admitted to an intensive care unit, and 46 (29%) required mechanical ventilation. Four in-hospital deaths occurred. Of 86 patients interviewed, 71 (83%) reported vaping tetrahydrocannabinol (THC)-containing products, 36 (43%) cannabidiol (CBD)-containing products, and 39 (47%) nicotine-containing products. Sixty-five of 87 (75%) THC-containing products were reported as obtained from informal sources, such as friends, acquaintances, or unlicensed retailers. Of 87 vaping products tested from 24 patients, 49 (56%) contained THC. Vitamin E or vitamin E acetate was found in 41 (84%) of the THC-containing products and no nicotine products.

CONCLUSIONS AND RELEVANCE: Patients' clinical outcomes and vaping behaviors, including predominant use of THC-containing products from informal sources, are similar to those reported by other states, despite California's legal recreational cannabis market. While most THC products tested contained vitamin E or vitamin E acetate, other underlying cause(s) of injury remain possible. The California Department of Public Health recommends that individuals refrain from using any vaping or e-cigarette products, particularly THC-containing products from informal sources, while this investigation is ongoing.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Heinzerling A, Armatas C, Karmarkar E, et al. Severe Lung Injury Associated With Use of e-Cigarette, or Vaping, Products-California, 2019. JAMA Intern Med. 2020. PMID: 32142111. doi:10.1001/jamainternmed.2020.0664

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。